Shenzhen S.E.
03:30:00 16/07/2024 am IST
5-day change
1st Jan Change
24.45
CNY
-0.49%
-0.65%
-18.96%
Wondfo Biotech (HK) Co., Limited announced that it expects to receive $10 million in funding from Guangzhou Wondfo Biotech Co.,Ltd
Wondfo Biotech (HK) Co., Limited announced that it will receive $10,000,000 in a round of equity funding from existing investor Guangzhou Wondfo Biotech Co.,Ltd (SZSE:300482) on January 25, 2019. Post the closing, the investor will retain its 100% stake in the company. The transaction has been approved by board of directors of the investor at 10th meeting of the 3rd directorate.
Guangzhou Wondfo Biotech Co.,Ltd Announces Board Changes
18/06
CI
Guangzhou Wondfo Biotech Co.,Ltd Announces Final Cash Dividend (A Shares) for Year 2023, Payable on June 5, 2024
30/05
CI
Wondfo Biotech's Unit Gets Emergency Use Authorization from US FDA
06/05
MT
Guangzhou Wondfo Biotech Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024
21/04
CI
Guangzhou Wondfo Biotech Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023
25/23/25
CI
Guangzhou Wondfo Biotech Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023
15/23/15
CI
Tranche Update on Guangzhou Wondfo Biotech Co.,Ltd's Equity Buyback Plan announced on July 5, 2023.
12/23/12
CI
Guangzhou Wondfo Biotech Co.,Ltd's Equity Buyback announced on July 5, 2023 has closed with 1,121,900 shares, representing 0.25% for CNY 30.1 million.
11/23/11
CI
Guangzhou Wondfo Biotech Co.,Ltd announces an Equity Buyback for CNY 50 million worth of its shares.
05/23/05
CI
Guangzhou Wondfo Biotech Co.,Ltd authorizes a Buyback Plan.
05/23/05
CI
Beijing PolySeq Technology Co., Ltd. announced that it has received CNY 100 million in funding from Guangzhou Wondfo Biotech Co.,Ltd, Guangzhou Sanmei Investment Management Center (Limited Partnership), Shangshi Capital, IDG Capital Partners Co., Ltd., Tsinghua Innovation Ventures
12/23/12
CI
Guangzhou Wondfo Biotech Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023
25/23/25
CI
Guangzhou Wondfo Biotech Co.,Ltd Approves the Cash Dividend for the Year 2022, Payable on 18 May 2023
25/23/25
CI
Announcement on Resolutions of the 2022 Annual General Meeting of Guangzhou Wondfo Biotech
21/23/21
CI
Guangzhou Huiyin Tianyue Nominates Mr.Ge Xinhua as Supervisor
10/23/10
CI
Guangzhou Wondfo Biotech Co.,Ltd Proposes Final Cash Dividend for the Year 2022
01/23/01
CI
Guangzhou Wondfo Biotech Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022
30/23/30
CI
Beijing PolySeq Technology Co., Ltd. announced that it expects to receive CNY 40 million in funding from Guangzhou Wondfo Biotech Co.,Ltd, Guangzhou Sanmei Investment Management Center (Limited Partnership), Shangshi Capital, IDG Capital Partners Co., Ltd., Tsinghua Innovation Ventures
20/23/20
CI
Investors bet on greed and fear as China loosens COVID grip
09/22/09
RE
Guangzhou Wondfo Biotech Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022
27/22/27
CI
Tranche Update on Guangzhou Wondfo Biotech Co.,Ltd's Equity Buyback Plan announced on September 26, 2022.
12/22/12
CI
Guangzhou Wondfo Biotech Co.,Ltd's Equity Buyback announced on September 26, 2022, has expired with 1,046,200 shares, representing 0.24% for CNY 30.10 million.
11/22/11
CI
Guangzhou Wondfo Biotech Co.,Ltd announces an Equity Buyback for CNY 50 million worth of its shares.
26/22/26
CI
Guangzhou Wondfo Biotech Co.,Ltd authorizes a Buyback Plan.
26/22/26
CI
Guangzhou Wondfo Biotech Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022
25/22/25
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Guangzhou Wondfo Biotech Co Ltd is a China-based company principally engaged in research, manufacture and sales of point-of-care testing (POCT) reagents, POCT instrument and related products. According to the testing result, the Company' products can be divided into qualitative testing products and quantitative testing products. According to the usage, the Company' products include pregnancy testing series, infectious diseases testing series, drugs (drug abuse) testing series and chronic disease testing series. The Company's products are used in POCT, clinical test, field test and personal health management, and other fields.
More about the company
Last Close Price
24.45
CNY
Average target price
33.54
CNY
Spread / Average Target
+37.20%
Consensus
1st Jan change
Capi.
-18.96% 1.59B -6.66% 12.28B +90.81% 8.54B -22.14% 6.58B +8.86% 5.77B -23.82% 3.48B +5.12% 2.54B +43.10% 2.41B -7.24% 2.3B -64.26% 2.07B
Diagnostic & Testing Substances
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
GUANGZHOU WONDFO BIOTECH CO.,LTD 
